TY  - JOUR
AU  - Arlt, Friederike A
AU  - Miske, Ramona
AU  - Machule, Marie-Luise
AU  - Broegger Christensen, Peter
AU  - Mindorf, Swantje
AU  - Teegen, Bianca
AU  - Borowski, Kathrin
AU  - Buthut, Maria
AU  - Rößling, Rosa
AU  - Sánchez-Sendín, Elisa
AU  - van Hoof, Scott
AU  - Cordero-Gómez, César
AU  - Bünger, Isabel
AU  - Radbruch, Helena
AU  - Kraft, Andrea
AU  - Ayzenberg, Ilya
AU  - Klausewitz, Jaqueline
AU  - Hansen, Niels
AU  - Timäus, Charles
AU  - Körtvelyessy, Peter
AU  - Postert, Thomas
AU  - Baur-Seack, Kirsten
AU  - Rost, Constanze
AU  - Brunkhorst, Robert
AU  - Doppler, Kathrin
AU  - Haigis, Niklas
AU  - Hamann, Gerhard
AU  - Kunze, Albrecht
AU  - Stützer, Alexandra
AU  - Maschke, Matthias
AU  - Melzer, Nico
AU  - Rosenow, Felix
AU  - Siebenbrodt, Kai
AU  - Stenør, Christian
AU  - Dichgans, Martin
AU  - Georgakis, Marios K
AU  - Fang, Rong
AU  - Petzold, Gabor C
AU  - Görtler, Michael
AU  - Zerr, Inga
AU  - Wunderlich, Silke
AU  - Mihaljevic, Ivan
AU  - Turko, Paul
AU  - Schmidt Ettrup, Marianne
AU  - Buchholz, Emilie
AU  - Foverskov Rasmussen, Helle
AU  - Nasouti, Mahoor
AU  - Talucci, Ivan
AU  - Maric, Hans M
AU  - Heinemann, Stefan H
AU  - Endres, Matthias
AU  - Komorowski, Lars
AU  - Prüss, Harald
TI  - KCNA2 IgG autoimmunity in neuropsychiatric diseases.
JO  - Brain, behavior and immunity
VL  - 117
SN  - 0889-1591
CY  - Orlando, Fla.
PB  - Academic Press
M1  - DZNE-2024-00244
SP  - 399 - 411
PY  - 2024
AB  - Autoantibodies against the potassium voltage-gated channel subfamily A member 2 (KCNA2) have been described in a few cases of neuropsychiatric disorders, but their diagnostic and pathophysiological role is currently unknown, imposing challenges to medical practice.We retrospectively collected comprehensive clinical and paraclinical data of 35 patients with KCNA2 IgG autoantibodies detected in cell-based and tissue-based assays. Patients' sera and cerebrospinal fluid (CSF) were used for characterization of the antigen, clinical-serological correlations, and determination of IgG subclasses.KCNA2 autoantibody-positive patients (n = 35, median age at disease onset of 65 years, range of 16-83 years, 74 
KW  - Animals
KW  - Humans
KW  - Male
KW  - Adolescent
KW  - Young Adult
KW  - Adult
KW  - Middle Aged
KW  - Aged
KW  - Aged, 80 and over
KW  - Female
KW  - Autoimmunity
KW  - Retrospective Studies
KW  - Autoantibodies
KW  - Seizures
KW  - Autoimmune Diseases of the Nervous System
KW  - Mammals
KW  - Kv1.2 Potassium Channel
KW  - Encephalitis
KW  - Hashimoto Disease
KW  - Autoantibody (Other)
KW  - Autoimmune dementia (Other)
KW  - Autoimmune encephalitis (Other)
KW  - Epilepsy (Other)
KW  - Immunotherapy (Other)
KW  - KCNA2 (Other)
KW  - Kv1.2 (Other)
KW  - Autoantibodies (NLM Chemicals)
KW  - KCNA2 protein, human (NLM Chemicals)
KW  - Kv1.2 Potassium Channel (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:38309639
DO  - DOI:10.1016/j.bbi.2024.01.220
UR  - https://pub.dzne.de/record/268498
ER  -